Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Prescient Therapeutics Limited ( (AU:PTX) ) has provided an update.
Prescient Therapeutics Limited reported a significant decrease in both revenue and losses for the half-year ending December 31, 2024. The company experienced a 48.3% drop in revenue from ordinary activities, while losses after tax decreased by 32.3% compared to the previous period. The reduction in losses is attributed to lower research and development expenses, as well as decreased corporate and administrative costs. The company’s net assets fell, primarily due to changes in trade creditors and an increase in research and development claims receivable. While no dividends were declared, the company received a notable R&D tax incentive, impacting their financial positioning.
More about Prescient Therapeutics Limited
Prescient Therapeutics Limited operates in the biotechnology industry, focusing on developing novel cancer treatments. The company is engaged in research and development activities to advance its primary products, which include targeted cancer therapies, aiming to address unmet medical needs in oncology.
YTD Price Performance: -6.00%
Average Trading Volume: 672,368
Technical Sentiment Consensus Rating: Buy
Current Market Cap: A$40.27M
See more data about PTX stock on TipRanks’ Stock Analysis page.
